Catalog Advanced Search
Liver Lesions 101Contains 2 Component(s) Recorded On: 04/25/2019
Webinar hosted by the Hepatology Associates Special Interest Group on April 25, 2019.
This session will cover principles of imaging characteristics of benign and malignant hepatic lesions. Attendees will also receive an overview of the Liver Imaging Reporting and Data System (LI-RADs) for imaging findings in liver lesions and common biomarkers associated with hepatocellular carcinoma. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.
Pediatric Liver Disorders SIG: Challenge of Fontan Associated Liver DiseaseContains 8 Component(s) Recorded On: 11/09/2018
AASLD's Pediatric Liver Disorders SIG: Challenge of Fontan Associated Liver Disease presented at The Liver Meeting® 2018.
The hemodynamic changes in Fontan circulation (the palliative intervention in single ventricle physiology) confer risk of liver complications, particularly congestive hepatopathy. This program will include descriptions of the hepatopathy, the pathobiology of Fontan associated liver fibrosis, available diagnostic tools including imaging techniques and transplant-related medical decision making in the context of a failing Fontan.
Career Development WorkshopContains 9 Component(s) Recorded On: 11/09/2018
AASLD's Career Development Workshop presented at The Liver Meeting® 2018.
This workshop will look at various training pathways for a career in hepatology. It will also describe various career opportunities in research, practice, education and industry, providing an overview of the rewards and challenges for each of these, and identify sources for research funding for fellows and junior faculty members.
Oren K. Fix
Oren K. Fix, MD, MSc, FAASLD is Medical Director of the Liver Transplant Program at Swedish Medical Center in Seattle. He earned his medical degree at SUNY Buffalo School of Medicine and a masters degree in Epidemiology from Boston University School of Public Health. He completed his Internal Medicine residency and Gastroenterology fellowship at Boston University and Transplant Hepatology fellowship at University of California San Francisco (UCSF). Dr. Fix was a site principal investigator in the NIH-funded Acute Liver Failure Study Group for 8 years at University of Washington and UCSF. He has published over 45 peer-reviewed manuscripts and book chapters, many on the topic of acute liver failure.
Emily Rothbaum Perito
Kathleen E. Corey
Lawrence S. Friedman
Dr. Lawrence S. Friedman attended Princeton University and received his undergraduate and medical degrees from the Johns Hopkins School of Medicine combined BA/MD program. He did his residency training at Johns Hopkins Hospital, followed by a clinical and research fellowship in gastroenterology at Harvard Medical School and Massachusetts General Hospital. He was on the faculty of Jefferson Medical College, where he served as Vice Chairman of the Department of Medicine and a member of the Gastrointestinal Unit at Massachusetts General Hospital. He is Professor of Medicine at Harvard Medical School and Tufts University School of Medicine. Since July 1, 2003, he has been Chair of the Department of Medicine at Newton-Wellesley Hospital and Assistant Chief of Medicine at Massachusetts General Hospital.
Mark W. Russo
Non-alcoholic Fatty Liver Disease SIG: Advances in Genetics and Epigenetics in NAFLD: From Pathogenesis to Personalized MedicineContains 7 Component(s) Recorded On: 11/09/2018
AASLD's Non-alcoholic Fatty Liver Disease SIG: Advances in Genetics and Epigenetics in NAFLD: From Pathogenesis to Personalized Medicine presented at The Liver Meeting® 2018.
This program will detail recent advances in the understanding of genetic and epigenetic alterations that influence NAFLD and its progression. It will emphasize their impact on the natural history of NAFLD and variability in clinical outcomes. Details on how patient based epigenetic association studies have led to novel insights into disease pathogenesis will be outlined with an emphasis on how this may translate to new therapeutics. Finally, the role of genetics and epigenetics in the evaluation of the patient in the clinic will be addressed – with particular reference to diagnosis, prognosis and therapeutics.
Liver Transplantation and Surgery SIG & Surgery and Liver Transplantation Cmte: Combined Organ TransplantsContains 11 Component(s) Recorded On: 11/10/2018
AASLD's Liver Transplantation and Surgery SIG & Surgery and Liver Transplantation Cmte: Combined Organ Transplants presented at The Liver Meeting® 2018.
This program will review the current status of liver transplantation in the setting of combined organ transplants (i.e., liver/intestine/multi-visceral, liver/ kidney, liver/heart and liver/lung transplantation). Indications, pathophysiology, operative management, post-transplant care and outcomes will be discussed in the context of specific extra-hepatic organ dysfunction and combined organ transplantation. The session will also address the immunologic, ethical, financial and operational issues associated with multi-organ transplant as well as integration of these combined organ transplants in the overall liver allocation framework.
Richard Shane Mangus
Patrick S. Kamath
Josh Levitsky, MD, MS is currently a Professor of Medicine and Surgery in the Division of Gastroenterology & Hepatology at the Northwestern University Feinberg School of Medicine. Dr. Levitsky received his B.S. from the University of Michigan and M.D. from the Albert Einstein College of Medicine. He then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Chicago Hospitals and a Transplant Hepatology fellowship at the University of Nebraska Medical Center, receiving an AASLD Fellowship Award. He is currently certified by the American Board of Internal Medicine in Gastroenterology and Transplant Hepatology. At Northwestern, he completed a Master of Science in Clinical Investigation, is the Director of Liver Research, and is the program director for both Gastroenterology and Transplant Hepatology Fellowships. He has been elected to the Northwestern Feinberg Academy of Medical Educators and has received several teaching awards.
Dr. Levitsky is an active member of several professional societies, including the American Society of Transplantation and International Liver Transplantation Society where he served on the executive boards, as well as the AASLD where he has served on several committees. He is a Deputy Editor for the American Journal of Transplantation and on the Editorial Board for HEPATOLOGY. Dr. Levitsky’s academic interests are clinical and translational in nature, with a focus on liver transplant immunosuppression, tolerance and biomarkers. He previously received an AASLD Career Development Award in Liver Transplantation and has published numerous peer-reviewed journal articles, abstracts, book chapters and reviews on topics relevant to liver disease and transplantation. He is the principal and co-investigator for a number of NIH, pharmaceutical and investigator-initiated trials. His goal is to advance clinical/translational research in immune-mediated liver diseases and liver transplantation, identifying biomarkers and novel strategies to optimize outcomes.
2018 Clinical Hepatology DebriefContains 2 Component(s) Recorded On: 11/13/2018
AASLD's Clinical Hepatology Debrief presented at The Liver Meeting® 2018.
This session provides a summary of the clinical highlights from The Liver Meeting®.
Jorge A. Bezerra (Moderator)
K. Rajender Reddy
2018 Hepatitis DebriefContains 2 Component(s) Recorded On: 11/13/2018
AASLD's Hepatitis Debrief presented at The Liver Meeting® 2018.
This session provides a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting®.
Jorge A. Bezerra (Moderator)
Jordan J. Feld
Leon Schiff State-of-the-Art LectureContains 2 Component(s) Recorded On: 11/13/2018
AASLD's Leon Schiff State-of-the-Art Lecture presented at The Liver Meeting® 2018.
This lecture summarizes the current approach to understanding NASH pathogenesis, and how to translate recent advances into routine clinical care. Beginning with an overview of key pathogenic steps in development and progression of NASH, the program will also cover different therapeutic approaches for specific subsets of patients with NASH and related complications, and risk stratification of patients with respect to clinical outcomes.
Michael W. Fried (Moderator)
Arun J. Sanyal
2018 NAFLD DebriefContains 2 Component(s) Recorded On: 11/13/2018
AASLD's NAFLD Debrief presented at The Liver Meeting® 2018.
This session is designed to complement the highly-regarded, Hepatitis and Clinical Hepatology Debriefs, and will review key highlights from The Liver Meeting®.
Jorge A. Bezerra (Moderator)
Mary E. McCarthy Rinella
Hyman J. Zimmerman Hepatotoxicity State-of-the-Art LectureContains 2 Component(s) Recorded On: 11/12/2018
AASLD's Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture presented at The Liver Meeting® 2018.
Patients with underlying chronic liver disease (CLD) may develop drug-induced liver injury during clinical care or in clinical trials, and it is associated with poor outcomes. This lecture discusses medications and herbal agents that are commonly implicated in DILI, risk factors, strategies for monitoring patients in clinical trials, guidelines for adjudicating suspected DILI events and outcomes associated with DILI in CLD.
Raymond T. Chung (Moderator)
Naga P. Chalasani